178 related articles for article (PubMed ID: 36864331)
1. Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies.
Abraham DS; Nguyen TPP; Blank LJ; Thibault D; Gray SL; Hennessy S; Leonard CE; Weintraub D; Willis AW
Neurotherapeutics; 2023 Mar; 20(2):375-388. PubMed ID: 36864331
[TBL] [Abstract][Full Text] [Related]
2. Pregabalin add-on for drug-resistant focal epilepsy.
Panebianco M; Bresnahan R; Hemming K; Marson AG
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005612. PubMed ID: 31287157
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy.
Pan Y; Davis PB; Kaebler DC; Blankfield RP; Xu R
Cardiovasc Diabetol; 2022 Sep; 21(1):170. PubMed ID: 36050764
[TBL] [Abstract][Full Text] [Related]
4. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model.
Stepanović-Petrović R; Micov A; Tomić M; Pecikoza U
Psychopharmacology (Berl); 2017 Jun; 234(11):1781-1794. PubMed ID: 28332005
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
7. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
9. Pregabalin: new drug. Very similar to gabapentin.
Prescrire Int; 2005 Dec; 14(80):203-6. PubMed ID: 16397976
[TBL] [Abstract][Full Text] [Related]
10. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Cooper TE; Wiffen PJ; Heathcote LC; Clinch J; Howard R; Krane E; Lord SM; Sethna N; Schechter N; Wood C
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012536. PubMed ID: 28779491
[TBL] [Abstract][Full Text] [Related]
11. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011412. PubMed ID: 28661008
[TBL] [Abstract][Full Text] [Related]
12. A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
O'Connor AB; Noyes K; Holloway RG
Pharmacoeconomics; 2008; 26(12):1045-64. PubMed ID: 19014205
[TBL] [Abstract][Full Text] [Related]
13. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Weston J; Tudur Smith C; Marson AG
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011412. PubMed ID: 29243813
[TBL] [Abstract][Full Text] [Related]
14. Pregabalin add-on for drug-resistant focal epilepsy.
Panebianco M; Bresnahan R; Marson AG
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD005612. PubMed ID: 35349176
[TBL] [Abstract][Full Text] [Related]
15. Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?
Pham Nguyen TP; Abraham DS; Thibault D; Weintraub D; Willis AW
BMC Neurol; 2021 Jun; 21(1):240. PubMed ID: 34167473
[TBL] [Abstract][Full Text] [Related]
16. WITHDRAWN: Anticonvulsants for fibromyalgia.
Üçeyler N; Sommer C; Walitt B; Häuser W
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD010782. PubMed ID: 28991361
[TBL] [Abstract][Full Text] [Related]
17. Pregabalin for neuropathic pain in adults.
Derry S; Bell RF; Straube S; Wiffen PJ; Aldington D; Moore RA
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD007076. PubMed ID: 30673120
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
19. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Klein P; Friedman A; Hameed MQ; Kaminski RM; Bar-Klein G; Klitgaard H; Koepp M; Jozwiak S; Prince DA; Rotenberg A; Twyman R; Vezzani A; Wong M; Löscher W
Epilepsia; 2020 Mar; 61(3):359-386. PubMed ID: 32196665
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
